In the COMBAT study, small molecule CXCR4 inhibitor motixafortide improved patient response and OS in metastatic PDAC patients in combination with pembrolizumab.616 Mavorixafor, another CXCR4 inhibitor, sensitized patients with advanced RCC to nivolumab.617 Further investigations into the mechanisms underlying the multifarious chemokine axes as well as the development of chemokine-based immunotherapies are expected. The gene discussed is CXCR4; the disease is renal cell carcinoma.